Introduction
============

Glioblastoma (GBM) is the most common and malignant form of primary brain tumors. Despite recent progress in their treatment, median survival is still under 2 years. Nowadays, the main factors for increased survival rates in GBM are extensive surgical resection, age less than 65 years and combined adjuvant radio-chemotherapy.^[@B1]^

From 23% to 50% of GBM patients, seizures were the onset symptom of tumor.^[@B2]^ Epilepsy at presentation was associated with longer survival in some studies.^[@B2]--[@B6]^ However, the prognostic value of this finding remains controversial.^[@B7]^

The aim of this study is to assess the prognostic relevance of epilepsy on survival in GBMs patients and its relationship with other clinical, radiological and surgical factors.

Materials and Methods
=====================

The study population included 139 patients with histologically confirmed de novo supratentorial GBM treated at our Institution from January 2006 to December 2008. The study follow-up cut-off point was October 2009. Age, sex, Karnofsky performance status (KPS) at admission and at discharge, presentation symptoms (including presence of seizures or not), tumor location, type of surgery (resection or biopsy), extent of resection and adjuvant therapy were retrospectively collected and evaluated.

Seizures were classified according to the 2010 criteria of the International League Against epilepsy: focal without impairment of consciousnessfocal with impairment of consciousnessfocal evolving to bilateral convulsive seizure

We routinely give anti-epileptic drugs (AEDs) as prophylaxis in all operated patients even if they have not history of seizures. In all patients, we administer Levetiracetam.

In addition, all patients were evaluated for treatment with AEDs.

Pre-operative magnetic resonance imaging (MRI) imaging was carried out with 1,5-T system in all patients and the following features were evaluated: tumor size, location, invasion, extension, peritumoral edema, necrosis, bleeding and contrast enhancement.

Surgery consisted of either resection or biopsy. Extent of resection was classified according to post-operative computed tomography (CT) or MRI with contrast as follows: Gross total resection (GTR): lack of contrast enhancementSubtotal resection (STR): presence of contrast medium enhancement in less than 10% of the surgical cavityPartial resection (PR): contrast medium enhancement in less than 30% of the surgical cavity

The standard treatment following surgical resection includes radiotherapy (XRT) plus concomitant and adjuvant temozolomide (TMZ), according to Stupp's protocol.^[@B8]^ Oncologic treatment was considered complete in patients who had received at least one full cycle of XRT and TMZ.

Tumor progression was diagnosed through clinical and radiological assessment at regular intervals (usually by monitoring MR images every three months) during the follow-up.

The outcome was evaluated by analyzing the overall survival (OS) and progression-free survival (PFS). OS was defined as the time from the first surgery to death or until October 31, 2009, the cut-off point of follow-up. PFS was defined as the time from the first surgery to first evidence of tumor progression on CT or MR.

Survival was analyzed according to Kaplan--Meier survival curves using the log-rank test to determine statistical significance between groups and simple Cox models to assess differences in continuous variables. Multivariate analysis was performed using an adjusted Cox regression model in order to identify factors independently associated with better rates of survival during follow-up. A *P*-value \< 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 17.0 for Mac.

Results
=======

A complete follow-up was achieved for all 139 patients. At the end of the follow-up, 129 patients were dead (92.8%) and 10 were alive (7.2%). The study population included 85 males and 54 females with a mean age of 62 years (range from 25 to 86 years).

The most frequent clinical onset symptoms were focal neurological deficits, mainly motor deficit, followed by hemianopsia, sensory symptoms and aphasia occurred in 64 patients (46%). Epileptic seizures were the second most common presenting symptom occurred in 50 patients out of 139 (35.9%). Finally, at clinical onset 25 patients out of 139 (18%) showed headache and deterioration of consciousness.

The most frequent type of seizures was focal evolving to bilateral convulsive seizure (27 patients, 54%), with impairment of consciousness (13 patients, 26%) and finally focal seizure without impairment of consciousness (10 patients, 20%).

Status epilepticus with convulsive features was observed as onset symptom in only one patient with lumbar trauma with paraparesis. This patient underwent immediate surgical vertebral decompression and stabilization with screws and rods for unstable L1 burst fracture.^[@B9],[@B10]^ During chemotherapy the same patient developed L1 spondilodiscitis, level of previous surgery, treated with antibiotic therapy without hardware removal.^[@B11]^

Before surgery, 102 patients (73%) presented a KPS \> 70 while 37 patients (27%) a KPS \< 70. The location of GBM was: temporal in 53 patients (39%), frontal in 49 patients (35%), parietal in 21 patients (15%). The remaining 16 cases included lesions deeply seated (such as those located in the basal ganglia and/or corpus callosum) and/or lesions with multicentric locations and they were treated with biopsy.^[@B12]^

123 patients (88%) were treated with craniotomy and tumor resection while 16 (12%) with biopsy. Extension of resection was total in 62 patients (44%), subtotal with residual \<10% in 30 patients (22%) and partial in 31 patients (22%).

85 patients (61%) had radiotherapy (XRT) plus concomitant and adjuvant temozolomide (TMZ) according to Stupp's protocol, 13 (9%) and 16 (12%) respectively only XRT or chemotherapy (CT) and finally 25 patients (25%) did not receive adjuvant therapy at all.

The median OS in the total cohort of patients was 9 months from surgery. Survival probabilities to 1, 2 and 3 years were 35%, 8% and 4%, respectively.

At univariable Cox regression, the factors that significantly improved the OS were aged below 65 years (*P* = 0.0015), complete surgical resection (*P \<* 0.001), pre-operative Karnofsky performance status (KPS) \> 70 (*P* = 0.015), frontal location (*P \<* 0.001), XRT plus concomitant and adjuvant TMZ (*P \<* 0.001).

Epilepsy was not significantly associated with longer OS, with a median survival in the epilepsy group of 10 months versus 7 months for patients without epilepsy (*P* = 0.07).

Only in the subgroup of patients with focal seizures without impairment of consciousness, epilepsy was associated with an increased significant OS at univariate analysis (*P* = 0.043).

Multivariable Cox regression showed that complete surgical resection (*P \<* 0.0001), age below 65 years (*P* = 0.008), frontal location (*P* = 0.0001) and XRT plus concomitant and adjuvant TMZ (*P \<* 0.0001) were independent factors of longer survival.

These results were summarized in [Table 1](#T1){ref-type="table"}.

The mean PFS in our series was 5 months with 16 patients (12%) without tumor progression at 1 year from surgery. The univariate PFS analysis showed that complete surgical resection (*P \<* 0.0001), age below 65 years (*P* = 0.002), frontal location (*P* = 0.0001), pre-operative KPS \> 70) (*P* = 0.004) and XRT plus concomitant and adjuvant TMZ (*P* = 0.0001) were significant predictors of lengthier PFS. Multivariate analysis confirmed all the above-mentioned variables except the pre-operative KPS as independent predictors of longer PFS.

Finally, we analyzed the age, KPS, tumor location, extent of resection and adjuvant therapy as prognostic factors categorizing two groups of patients according to epileptogenic GBM (epilepsy+ vs epilepsy−). Age and extent of resection are statistically significant factors for the prognosis: epileptic patients are younger than non-epileptic (*P* = 0.0001) and presented an increased rate of gross total tumor resection (*P* = 0.017) with subsequent better prognosis. These data are summarized in [Table 2](#T2){ref-type="table"}.

Discussion
==========

In neuro-oncology the identification of prognostic factors is essential to stratify patients in relatively homogeneous classes of therapies.

In the recently published guideline by the European Association for Neuro-Oncology (EANO) for diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, age and pre-operative KPS together with genetic and molecular markers (such as IDH mutation and 1p/19q codeletion), are the guide for adjuvant or palliative therapies after surgery for GBMs.^[@B13]^ Furthermore, these guidelines point out the extent of resection as a positive prognostic factor for survival and recommended maximum safe resection in all patients with newly diagnosed gliomas, including GBM.^[@B2]--[@B7],[@B13],[@B14])^

In our series, the extent of resection was an independent prognostic factor both for OS and PFS. In fact, the GTR patients group presented a median OS of 14 months compared to the 6 months of non-GTR group (STR, PR or biopsy). In relation to PFS, GTR group had a median of 9 months free from GBM progression while non-GTR group had PFS time of 3 months. In the non-GTR group we included patients treated with STR, PR or biopsy because the median OS was similar in both groups (6 months).

Younger age and better KPS are well-known important positive prognostic factors for GBMs in literature.^[@B2]--[@B5],[@B13])^ In the present study only age below 65 years was a significant prognostic factor for longer OS both in uni and multivariate analysis. Pre-operative KPS was associated with better OS only at univariate Cox regression. This issue may be explained by the fact that in our series nearly every patient had a KPS \> 70 (102 patients out of 139) with subsequent reduction of statistical significance.

Among prognostic factors, onset epilepsy has been associated with longer survival in several studies.^[@B2]--[@B6]^ However, its prognostic relevance in GBM is still controversial.^[@B7]^

Some authors hypothesized that seizures at clinical onset lead to tumor early diagnosis and this leads to longer survival.^[@B2],[@B6]^ However, this is not proven yet.

In this regard, Toledo et al.^[@B6]^ in a prospective observational study recruited 56 patients with GBM and seizures as presenting symptoms were observed in 26.6% patients. In this study, epilepsy was associated with longer survival only in patients younger than 60 years. However, the imaging and histological features found no evidence indicating that epileptogenic GBM is at an earlier stage at the time of the diagnosis.

Moreover, a recent retrospective series of 647 consecutive patients diagnosed with de novo GBMs showed a favorable association between epilepsy at clinical presentation and prolonged survival.^[@B4]^ This positive correlation is independent of age, sex, KPS, extent of resection, adjuvant therapy, tumor location and volume. For these reasons, the authors postulated that this positive association cannot be attributed solely to early diagnosis, but it might result from distinct genetic and biological features of epileptogenic GBMs.

The present study investigates the clinical features of seizures in GBMs and the value of epilepsy on GBMs survival time. Epilepsy in our series was the second most common presenting symptoms (36% of patients) in GBMs followed by neurological deficit, which occurred in 64 patients (46%). At univariate analysis, epilepsy at clinical presentation was not significantly associated with longer OS. These data do not appear in line with recent literature showing an association between epileptic onset and longer survival, except for a 2016 study of Shin (at any time during the course of glioblastoma) in which seizure was associated with significantly increased survival.^[@B7]^

In this scenario, Flanigan et al.^[@B5]^ recently published a retrospective series of 443 patients with pre-operative rate of seizure of 28% in which multivariate analysis revealed pre-operative epilepsy to be independently associated with increased survival. However, the same authors reported that, in case of longer delay between time of epilepsy at clinical onset and surgery, the prognostic benefit of pre-operative seizure does not seem significant. The same authors explain also that seizures usually arise from small lesions so their prognostic benefit only occurs when surgical intervention is prompt before more symptoms, a marker of tumor progression.

The present study analyzes the impact of epilepsy among different types of clinical onset: in this case the relative better OS in the epilepsy group was not significant compared to the neurological deficit group with respectively a median OS of 10 and 7 months. Moreover, in our study only 29 patients out of 50 with epilepsy were treated with GTR. This issue was correlated to the higher number of epileptogenic GBMs located close to eloquent areas. This observation has not been previously reported. In this study epilepsy was not significantly associated with longer survival, the median survival in the epilepsy group was 10 months versus 7 months for patients without epilepsy at clinical onset (*P* = 0.07).

In our study, the analysis of all epileptic patients (50 pts) does not show any statistically positivity because probably many patients (27 out of 50) had bilateral convulsive seizure due to a wide diffusion of the tumor in the brain (late stage of disease). A second hypothesis is that the small number of patients do not allow a relevant and specific statistical analysis.

Finally, only in the subgroup of patients with focal seizures without impairment of consciousness, epilepsy was associated with an increased significant OS at univariate analysis (*P* = 0.043). This could be explained by the fact that partial focal seizures without impairment of consciousness at presentation would lead to detection of the tumor at an earlier stage and this factor would imply longer survival.

In our series, young epileptogenic and high resected tumors had a good prognosis because epilepsy as presenting symptom allows a prompt diagnosis so in young patients without comorbidities the maximal surgical and adjuvant therapy may be feasible.

Conclusions
===========

In our series epilepsy at clinical presentation is not an independent prognostic factor for longer survival in GBM patients. Only in the subgroup of patients with focal seizures without impairment of consciousness, epilepsy was associated with an increased significant OS at univariate analysis (*P* = 0.043).

The main independent factors that predict a relatively favorable outcome in GBMs remain complete tumor resection, followed by combined XRT-TMZ, frontal location and patient under 65 years old.
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###### 

Results of univariable and multivariable Cox regression of the main factors that affect median overall survival

  Variable                                         No. of patients   Median overall survival (months)   Univariate analysis   Multivariate analysis
  ------------------------------------------------ ----------------- ---------------------------------- --------------------- -----------------------
  **Age**                                                                                               0.0015                0.008
  \<65 years                                       69                12 ± 2.1                                                 
  \>65 years                                       70                8 ± 1.8                                                  
  **KPS**                                                                                               0.013                 \>0.05
  \>70                                             102               10 ± 1.7                                                 
  \<70                                             37                6 ± 1.2                                                  
  **Location**                                                                                          \<0.0001              0.0001
  Frontal                                          49                11 ± 1.9                                                 
  Temporal                                         53                10 ± 2.1                                                 
  Parietal                                         21                8 ± 2.4                                                  
  Occipital                                        4                 3 ± 0.7                                                  
  Bilateral                                        3                 2 ± 0.9                                                  
  Multicentric                                     9                 3 ± 1.1                                                  
  **Extent of Resection**                                                                               \<0.0001              \<0.0001
  GTR                                              62                14 ± 2.9                                                 
  STR, partial, biopsy                             77                6 ± 1.6                                                  
  **Adjuvant Therapy**                                                                                  \<0.0001              \<0.0001
  XRT+TMZ                                          85                12 ± 2.2                                                 
  XRT                                              13                7 ± 1.6                                                  
  CT                                               16                6 ± 1.4                                                  
  No adjuvant therapy                              25                3 ± 0.9                                                  
  **Epilepsy at presentation**                                                                          0.07                  \>0.05
  Yes                                              50                10 ± 2.3                                                 
  No                                               89                7 ± 1.6                                                  
  **Type of Seizure at Presentation**                                                                   0.043                 \>0.05
  Focal without impairment of consciousness        10                14 ± 2.3                                                 
  Focal with impairment of consciousness           13                8 ± 1.5                                                  
  Focal evolving to bilateral convulsive seizure   27                6.5 ± 1.1                                                

CT: chemotherapy, GTR: gross total resection, STR: subtotal resection, TMZ: temozolamide, XRT: radiotherapy.

###### 

Characteristics of subgroups analyzed in this study and the data of median overall survival in the subgroup of epileptogenic GBM and non-epileptogenic GBM

  Variable                  No. of patients   Epilepsy group (50 patients)   Median overall survival (months)   No epilspy group (138 patients)   Median overall survival (months)   *P* value   Odds ratio   CI 95%
  ------------------------- ----------------- ------------------------------ ---------------------------------- --------------------------------- ---------------------------------- ----------- ------------ ------------
  **Age**                                                                    12 ± 2.2                                                             8 ± 2.4                            0.0001      4.36         2.06--9.26
  \<65 years                69                36                                                                33                                                                                            
  \>65 years                70                14                                                                56                                                                                            
  **KPS**                                                                    10 ± 1.7                                                             7 ± 1.2                            0.6         1.24         0.56--2.74
  \>70                      102               38                                                                64                                                                                            
  \<70                      37                12                                                                25                                                                                            
  **Location**                                                               10 ± 2.1                                                             8 ± 2.4                            0.83        1.18         0.48--5.26
  Frontal                   49                24                                                                25                                                                                            
  Temporal                  53                20                                                                33                                                                                            
  Parietal                  21                6                                                                 15                                                                                            
  Occipital                 4                 0                                                                 4                                                                                             
  Bilateral                 3                 0                                                                 3                                                                                             
  Multicentric              9                 0                                                                 9                                                                                             
  **Extent of resection**                                                    14 ± 2.9                                                             7 ± 1.6                            0.017       2.34         1.16--4.75
  GTR                       62                29                                                                33                                                                                            
  STR, partial, biopsy      77                21                                                                56                                                                                            
  **Ajuvant therapy**                                                        12 ± 2.2                                                             11 ± 1.9                           0.38        2.48         0.78--8.49
  XRT+TMZ                   85                31                                                                54                                                                                            
  XRT                       13                10                                                                3                                                                                             
  CT                        16                3                                                                 13                                                                                            
  No adjuvant therapy       25                6                                                                 19                                                                                            

CT: chemotherapy, GTR: gross total resection, STR: subtotal resection, TMZ: temozolamide, XRT: radiotherapy.
